Cargando…

OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression

Detalles Bibliográficos
Autores principales:	Moran, Amy, Polesso, Fanny, Weinberg, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288330/ http://dx.doi.org/10.1186/2051-1426-2-S3-O18

Ejemplares similares

Finding the right balance: aOX40 immunotherapy enhances effector T cell function without impairing regulatory T cells intrinsic suppressive capacity in mouse tumor models
por: Moran, Amy, et al.
Publicado: (2015)

STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors
por: Akporiaye, Emmanuel T, et al.
Publicado: (2013)

Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination
por: Chu, Yanhong, et al.
Publicado: (2021)

Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging
por: Farazi, Michelle, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
por: Crosby, Erika J., et al.
Publicado: (2018)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)

Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression
por: Yu, Guangjie, et al.
Publicado: (2016)

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
por: Kim, Tae Won, et al.
Publicado: (2022)

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
por: Sun, Zhichen, et al.
Publicado: (2023)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade
por: Rossi, Alessandra, et al.
Publicado: (2020)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy
por: Boss, Mary-Keara, et al.
Publicado: (2022)

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2014)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Zhang, Jing, et al.
Publicado: (2022)

OX40: a win–win path to tumor immunity
por: Sedwick, Caitlin
Publicado: (2008)

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization
por: Gee, Julia MW, et al.
Publicado: (2003)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2017)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
por: Duhen, Rebekka, et al.
Publicado: (2021)

The Role of OX40 (CD134) in T-Cell Memory Generation
por: Weinberg, Andrew D.
Publicado: (2010)

Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist
por: Pieper, Alexander A., et al.
Publicado: (2023)

Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
por: Pilones, Karsten, et al.
Publicado: (2014)

Prevalence analysis of OX40-positive cell populations in solid tumors
por: Ziai, James, et al.
Publicado: (2015)

OX40L blockade and allergen-induced airway responses in subjects with mild asthma
por: Gauvreau, G M, et al.
Publicado: (2014)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade
por: Xue, Ying, et al.
Publicado: (2023)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors
por: Scherwitzl, Iris, et al.
Publicado: (2020)

Whole body irradiation and agonist anti-CD40 synergize to promote adoptive T cell therapy of resistant murine pancreatic neuroendocrine tumors
por: Ward-Kavanagh, Lindsay, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k290vcc3l4dc4q0h2hkpglrjbv